Summary
Several recent case control studies have shown an exess rate of venous thromboembolism in women using third generation progestogen-containing combined contraceptive pills compared to second generation combined contraceptive pills. This excess is about 1 in 10 000 women per year of use. It is likely that second and third generation pills have been preferentially prescribed to users who have varying susceptiblity to venous thromboembolism and that this may account for at least part of the observed differences. In practice, it is essential that all women using combined oral contraceptive pills have a thorough history taken to exclude any contraindications or risk factors. Each client should be counselled about the risks and benefits of oral contraception. In New Zealand, the Ministry of Health has recommended that prescribers for women starting a contraceptive pill for the first time should consider a pill that does not contain a third generation progestogen. Women already receiving a third generation pill may elect to continue that pill after the differential rates of venous thromboembolism have been discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995 Dec 16; 346: 1575–82
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995 Dec 16; 346: 1582–8
Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995 Dec 16; 346: 1589–93
Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996 Jan 13; 312: 83–8
Lewis MA, Spitzer WO, Heinemann LAJ, et al. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. BMJ 1996 Jan 13; 312: 88–90
Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deepvein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995 Dec 16; 346: 1593–6
Spitzer WO. Data from Transnational Study of Oral Contraceptives have been misused [letter]. BMJ 1995 Oct 28; 311: 1162
Westhoff CL. Oral contraceptives and venous thromboembolism: should epidemiologic associations drive clinical decision making? Contraception 1996; 54: 1–3
Lewis MA, Heinemann LAJ, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996; 54: 5–13
Lidegaard O, Milsom I. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception 1996; 53: 135–9
New Zealand Ministry of Health. Advice on the use of combined oral contraceptives. Prescriber Update 1996 Jul; 12: 2–5
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roke, C. Oral Contraception and Venous Thromboembolism. Drug-Safety 16, 79–87 (1997). https://doi.org/10.2165/00002018-199716020-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199716020-00001